Aptiva Medical, a prominent provider of continuous glucose monitoring (CGM) systems in the United States, has completed its acquisition of VeraMed Health, a move aimed at expanding its national patient base and enhancing its operational capabilities in diabetes management. The announcement was made on October 7, 2025, from the company’s headquarters in Fort Lauderdale, Florida.
This acquisition is expected to significantly bolster Aptiva Medical’s referral and payor networks, further accelerating its growth trajectory. The integration of VeraMed Health aligns with Aptiva’s commitment to delivering innovative solutions for diabetes management to patients nationwide.
Strengthening Leadership in Diabetes Management
Greenleaf Ventures, the private investment firm backing Aptiva Medical, has a proven history in the healthcare sector. Co-founders Timothy Stocksdale and David Wallace have successfully built and scaled several healthcare companies, including Access Diabetic Supply and Arriva Medical. Their expertise in navigating the complexities of the medical supply and pharmacy sectors positions Aptiva Medical for continued success following this acquisition.
David Wallace remarked, “This acquisition aligns perfectly with Aptiva Medical’s mission to build a leading, nationwide direct-to-patient CGM business. The VeraMed team has built an excellent foundation of patient care, and Aptiva Medical will ensure a seamless transition for every patient while continuing to raise the bar on service and efficiency.”
Aptiva Medical is recognized for its comprehensive patient support services, which include prescription coordination, insurance billing, and home delivery of CGMs and diabetes testing supplies. The company’s approach emphasizes collaboration with healthcare providers and payors to enhance patient adherence and health outcomes.
Future Prospects
The acquisition of VeraMed Health not only expands Aptiva Medical’s footprint but also strengthens its position in a competitive market. With the growing prevalence of diabetes, the demand for effective management solutions continues to increase. This strategic move is anticipated to improve access to essential diabetes management tools for patients across the country.
Greenleaf Ventures, with a focus on healthcare investments, has previously demonstrated its ability to successfully turn around companies. This acquisition adds to its portfolio of healthcare ventures, which boasts a collective enterprise value exceeding $500 million.
Aptiva Medical’s commitment to enhancing the patient experience and expanding its services is likely to contribute positively to the future of diabetes management in the United States. As the company integrates VeraMed Health, stakeholders will be watching closely to see how this partnership enhances patient care and operational efficiency in the coming months.
